Bibliometric Insights into CRISPR-Cas9 Research Targeting Human Disease Pathology
Bibliographic Data
| ID | 22006463 |
|---|---|
| Authors | Moutaz W Sweileh (0000-0002-7130-156X, An-Najah National University, corresponding author) |
| Year | 2026 |
| Volume | 16 |
| Issue | 1 |
| Publication date | 2026-01-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | SAGE Open (JOURNAL) |
| Journal identifiers | ISSN: 2158-2440 • E-ISSN: 2158-2440 |
| Publisher | SAGE Publications (PUBLISHER • US) |
| DOI | 10.1177/21582440261415669 |
| OpenAlex | W7125503378 |
| Language | EN |
| References cited | 111 |
CRISPR-Cas9 has rapidly emerged as a transformative genome editing platform. To analyze and map scientific research on CRISPR-Cas9 in the context of human disease pathology. A bibliometric study was conducted on original research articles indexed in Scopus between 2010 and 2024, focused on CRISPR-Cas9 applications in human disease pathology. A total of 4,313 publications were identified with an average annual growth rate of 54.5% and an H-index of 146. The top publishing journals were Scientific Reports, International Journal of Molecular Sciences , and Nature Communications. The United States led with 1,727 articles, followed by China ( n = 1,355), with 50.9% international collaboration for the United States versus 34.4% for China. The average number of authors per article was 10.8. The top-cited article reported on CRISPR-Cas9 therapy for beta-thalassemia and sickle cell disease, followed by major studies on cystic fibrosis, amyloidosis, muscular dystrophy, and colorectal cancer. The following research themes were identified: (1) cancer pathways and metastasis (2) viral genome targeting; (3) mutation-driven genetic disorders; and (4) hematological disorders. VOSviewer maps indicated that off-target effects, delivery methods, and ethical concerns are major challenges for CRISPR-Cas9 use in human diseases. The analysis reflects exponential scientific growth and translational momentum. Future research will require refined delivery strategies, safety optimization, and ethical integration to fully harness CRISPR-Cas9’s clinical potential. Clinical Trial Registration : Not applicable
Bibliometrics · Clinical trial · Disease · MEDLINE · Publishing · Scopus · Transformative learning · Translational research · Biotechnology and Related Fields · CRISPR and Genetic Engineering · Intellectual Property and Patents
The new frontier of genome engineering with CRISPR-Cas9
Meeting the review family
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Comparison of PubMed, Scopus, Web of Science, and Google Scholar
The emergence of China as a leading nation in science
How to conduct a bibliometric analysis
An index to quantify an individual's scientific research output
A typology of reviews
The journal coverage of Web of Science and Scopus
Software survey
| Highly cited | No |
|---|